# Frontline Asciminib Combination in Chronic Phase CML

> **NCT03906292** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Jena** · enrollment: 125 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib 300 mg
- **DRUG:** Dasatinib
- **DRUG:** Asciminib

## Key facts

- **NCT ID:** NCT03906292
- **Lead sponsor:** University of Jena
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-19
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03906292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03906292, "Frontline Asciminib Combination in Chronic Phase CML". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03906292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*